TY - JOUR
T1 - Preparation and characterization of hydroxypropyl methyl cellulose films containing stable BCS Class II drug nanoparticles for pharmaceutical applications
AU - Sievens-Figueroa, Lucas
AU - Bhakay, Anagha
AU - Jerez-Rozo, Jackeline I.
AU - Pandya, Natasha
AU - Romañach, Rodolfo J.
AU - Michniak-Kohn, Bozena
AU - Iqbal, Zafar
AU - Bilgili, Ecevit
AU - Davé, Rajesh N.
N1 - Funding Information:
The authors thank NSF for financial support of this project through the ERC ( EEC-0540855 ) award. The authors also thank Golshid Keyvan for assistance with HPLC, Christian Beck for assistance with XRD, and Catharina Knieke for providing the FNB microparticles.
PY - 2012/2/28
Y1 - 2012/2/28
N2 - The design and feasibility of a simple process of incorporating stable nanoparticles into edible polymer films is demonstrated with the goal of enhancing the dissolution rate of poorly water soluble drugs. Nanosuspensions produced from wet stirred media milling (WSMM) were transformed into polymer films containing drug nanoparticles by mixing with a low molecular weight hydroxylpropyl methyl cellulose (HPMC E15LV) solution containing glycerin followed by film casting and drying. Three different BCS Class II drugs, naproxen (NPX), fenofibrate (FNB) and griseofulvin (GF) were studied. The influence of the drug molecule on the film properties was also investigated. It was shown that film processing methodology employed has no effect on the drug crystallinity according to X-ray diffraction (XRD) and Raman spectroscopy. Differences in aggregation behavior of APIs in films were observed through SEM and NIR chemical imaging analysis. NPX exhibited the strongest aggregation compared to the other drugs. The aggregation had a direct effect on drug content uniformity in the film. Mechanical properties of the film were also affected depending on the drug-polymer interaction. Due to strong hydrogen bonding with the polymer, NPX exhibited an increase in Young's Modulus (YM) of approximately 200%, among other mechanical properties, compared to GF films. A synergistic effect between surfactant/polymer and drug/polymer interactions in the FNB film resulted in an increase of more than 600% in YM compared to the GF film. The enhancement in drug dissolution rate of films due to the large surface area and smaller drug particle size was also demonstrated.
AB - The design and feasibility of a simple process of incorporating stable nanoparticles into edible polymer films is demonstrated with the goal of enhancing the dissolution rate of poorly water soluble drugs. Nanosuspensions produced from wet stirred media milling (WSMM) were transformed into polymer films containing drug nanoparticles by mixing with a low molecular weight hydroxylpropyl methyl cellulose (HPMC E15LV) solution containing glycerin followed by film casting and drying. Three different BCS Class II drugs, naproxen (NPX), fenofibrate (FNB) and griseofulvin (GF) were studied. The influence of the drug molecule on the film properties was also investigated. It was shown that film processing methodology employed has no effect on the drug crystallinity according to X-ray diffraction (XRD) and Raman spectroscopy. Differences in aggregation behavior of APIs in films were observed through SEM and NIR chemical imaging analysis. NPX exhibited the strongest aggregation compared to the other drugs. The aggregation had a direct effect on drug content uniformity in the film. Mechanical properties of the film were also affected depending on the drug-polymer interaction. Due to strong hydrogen bonding with the polymer, NPX exhibited an increase in Young's Modulus (YM) of approximately 200%, among other mechanical properties, compared to GF films. A synergistic effect between surfactant/polymer and drug/polymer interactions in the FNB film resulted in an increase of more than 600% in YM compared to the GF film. The enhancement in drug dissolution rate of films due to the large surface area and smaller drug particle size was also demonstrated.
KW - BCS Class II
KW - Hydroxylpropyl methyl cellulose
KW - Media milling
KW - Nanosuspensions
KW - Pharmaceutical films
UR - http://www.scopus.com/inward/record.url?scp=84856537441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856537441&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2011.12.001
DO - 10.1016/j.ijpharm.2011.12.001
M3 - Article
C2 - 22178619
AN - SCOPUS:84856537441
SN - 0378-5173
VL - 423
SP - 496
EP - 508
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 2
ER -